Lensar, INC DEF 14A proxy statements

LENSAR, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 18, 2025, for the election of Class II Directors and ratification of its independent auditor.

LENSAR, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 18, 2025, to elect Class II directors and ratify its independent accounting firm.

LENSAR, Inc. filed a supplement to its definitive proxy statement for the proposed merger with Alcon Research, LLC, providing additional disclosures to address shareholder demand letters alleging omitted material information.

LENSAR, Inc. and Alcon Research, LLC received a second request for information from the Federal Trade Commission (FTC) regarding their proposed merger, extending the waiting period under the Hart-Scott-Rodino Act.

Alcon Research, LLC is set to acquire LENSAR, Inc. for $14.00 per share in cash plus a contingent value right (CVR) of up to $2.75 per share, pending stockholder approval.

Alcon, a global leader in eye care, intends to acquire LENSAR, a move announced to LENSAR employees on March 24, 2025, with the transaction expected to close in mid-to-late 2025.

Alcon is set to acquire LENSAR, enhancing its cataract equipment portfolio with advanced laser technology.

LENSAR, Inc. is holding its annual stockholder meeting virtually on May 7, 2024, and has made proxy materials available for review and voting.

LENSAR, Inc. has scheduled its 2024 annual meeting of stockholders as a virtual event on May 7, 2024, to vote on the election of directors and ratification of the company's independent accounting firm.